Literature DB >> 7728748

Loss of imprinting in hepatoblastoma.

S Rainier1, C J Dobry, A P Feinberg.   

Abstract

We and others have described loss of imprinting (LOI) of the insulin-like growth factor II (IGF2) gene in 70% of Wilms' tumors (WT), an embryonal kidney tumor, and we have also found LOI of the H19 gene in 29% of WTs. In WT, LOI of IGF2 is coupled to down-regulation of H19. LOI of IGF2 has subsequently been described in a second embryonal neoplasm, rhabdomyosarcoma. However, the hypothesis that LOI is a general feature of embryonal tumors is challenged by a report of absence of LOI in three hepatoblastomas (S. M. Davies, Cancer Res., 53: 4781-4783, 1993). We identified five hepatoblastomas informative for a transcribed polymorphism of the IGF2 gene. One tumor showed LOI of IGF2, in contrast to the previous report. That tumor also showed LOI of H19, further documenting a role for this gene in imprinting disturbances in cancer. However, in contrast to WT, LOI in hepatoblastoma was not associated with down-regulation of H19. Thus, IGF2 and H19 expression can be uncoupled in tumors with LOI.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7728748

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  28 in total

Review 1.  Genomic imprinting: implications for human disease.

Authors:  J G Falls; D J Pulford; A A Wylie; R L Jirtle
Journal:  Am J Pathol       Date:  1999-03       Impact factor: 4.307

2.  p57(KIP2) is not mutated in hepatoblastoma but shows increased transcriptional activity in a comparative analysis of the three imprinted genes p57(KIP2), IGF2, and H19.

Authors:  W Hartmann; A Waha; A Koch; C G Goodyer; S Albrecht; D von Schweinitz; T Pietsch
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

3.  The product of the imprinted H19 gene is an oncofetal RNA.

Authors:  I Ariel; S Ayesh; E J Perlman; G Pizov; V Tanos; T Schneider; V A Erdmann; D Podeh; D Komitowski; A S Quasem; N de Groot; A Hochberg
Journal:  Mol Pathol       Date:  1997-02

Review 4.  Current and future management strategies for relapsed or progressive hepatoblastoma.

Authors:  Rajkumar Venkatramani; Wayne L Furman; Joerg Fuchs; Steven W Warmann; Marcio H Malogolowkin
Journal:  Paediatr Drugs       Date:  2012-08-01       Impact factor: 3.022

Review 5.  Epigenetic Determinants of Cancer.

Authors:  Stephen B Baylin; Peter A Jones
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-09-01       Impact factor: 10.005

Review 6.  Epigenetic modulators, modifiers and mediators in cancer aetiology and progression.

Authors:  Andrew P Feinberg; Michael A Koldobskiy; Anita Göndör
Journal:  Nat Rev Genet       Date:  2016-03-14       Impact factor: 53.242

7.  Phylogenetic footprint analysis of IGF2 in extant mammals.

Authors:  Jennifer R Weidman; Susan K Murphy; Catherine M Nolan; Fred S Dietrich; Randy L Jirtle
Journal:  Genome Res       Date:  2004-09       Impact factor: 9.043

8.  Pharmacological inhibition of beta-catenin in hepatoblastoma cells.

Authors:  V Ellerkamp; J Lieber; C Nagel; J Wenz; S W Warmann; J Fuchs; S Armeanu-Ebinger
Journal:  Pediatr Surg Int       Date:  2012-12-25       Impact factor: 1.827

9.  H19 overexpression in breast adenocarcinoma stromal cells is associated with tumor values and steroid receptor status but independent of p53 and Ki-67 expression.

Authors:  E Adriaenssens; L Dumont; S Lottin; D Bolle; A Leprêtre; A Delobelle; F Bouali; T Dugimont; J Coll; J J Curgy
Journal:  Am J Pathol       Date:  1998-11       Impact factor: 4.307

Review 10.  Pediatric Rhabdomyosarcoma.

Authors:  Jack F Shern; Marielle E Yohe; Javed Khan
Journal:  Crit Rev Oncog       Date:  2015
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.